NMD Pharma A/S
- Country
- 🇩🇰Denmark
- Ownership
- Holding
- Established
- 1986-03-13
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nmdpharma.com
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- NMD Pharma A/S
- Target Recruit Count
- 80
- Registration Number
- NCT06482437
- Locations
- 🇺🇸
University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States
🇺🇸Mass General Neurology, Boston, Massachusetts, United States
🇺🇸NextGen Precision Health, Columbia, Missouri, United States
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- Conditions
- Myasthenia GravisMyasthenia Gravis, MuSK
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- NMD Pharma A/S
- Target Recruit Count
- 84
- Registration Number
- NCT06414954
- Locations
- 🇺🇸
Profound Research LLC, Carlsbad, California, United States
🇺🇸University of California Irvine Medical Center, Irvine, California, United States
🇺🇸University of Colorado Neuromuscular Division, Aurora, Colorado, United States
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- NMD Pharma A/S
- Target Recruit Count
- 54
- Registration Number
- NCT05794139
- Locations
- 🇺🇸
UCLA David Geffen School Of Medicine - Neurology, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸UF Fixel Institute for Neurological Diseases, Gainesville, Florida, United States
Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls
- Conditions
- Charcot-Marie-Tooth Disease
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- NMD Pharma A/S
- Target Recruit Count
- 30
- Registration Number
- NCT04980807
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇩🇰Aarhus University Hospital, Aarhus, Jutland, Denmark
Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults
- Conditions
- Sarcopenia
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- NMD Pharma A/S
- Target Recruit Count
- 19
- Registration Number
- NCT04904926
- Locations
- 🇺🇸
Ohio University, Athens, Ohio, United States
News
SMA Clinical Trials Update: Investigational Therapies and Expanded Risdiplam Studies
• Several companies are advancing novel therapies for spinal muscular atrophy (SMA), with over 20 treatments currently in clinical development. • Roche is conducting a Phase IV open-label study to assess the effectiveness and safety of risdiplam in pediatric SMA patients following gene therapy. • Biogen is evaluating higher doses of intrathecally administered nusinersen to improve clinical efficacy in SMA patients. • Novartis is studying the safety and efficacy of intrathecal OAV101 in SMA patients who have discontinued nusinersen or risdiplam treatment.